Strategie
The Fund's investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China Biotech v2 Index Net Total Return (the 'Index').
The Fund is passively managed. The Fund will aim to achieve its investment objective by attempting to replicate the performance of the Index by investing primarily in a portfolio of equity securities that as far as possible and practicable consists of the component securities of the Index. The Fund may invest in China A-Shares of biotechnology companies. The Fund will invest in A-Shares included in the Index through Stock Connect, which may include stocks on the Small and Medium Enterprise Board and/or ChiNext Board of the Shenzhen Stock Exchange. The Fund may have exposure to or invest up to 20% of the Net Asset Value ('NAV') of the Fund in stocks issued by the same body. The Index aims to provide exposure to Chinese companies that are mainly active in the field of biotechnology. The Index universe includes listed shares of companies headquartered in mainland China or Hong Kong.